LOGAN FDC-6TA Vertical Transdermal Diffusion System
| Brand | LOGAN |
|---|---|
| Origin | USA |
| Manufacturer Type | Authorized Distributor |
| Origin Category | Imported Instrument |
| Model | FDC-6TA |
| Pricing | Available Upon Request |
Overview
The LOGAN FDC-6TA Vertical Transdermal Diffusion System is an engineered platform for in vitro assessment of drug permeation and release kinetics across biological or synthetic membranes. Designed in strict accordance with USP “Drug Release” and “Transdermal Delivery Systems”, as well as ISO 10993-12 for biocompatibility evaluation of medical devices, the FDC-6TA implements a vertical Franz-type diffusion cell configuration. This geometry ensures consistent hydrodynamic conditions, minimizes boundary layer disturbance, and enables precise control over donor–receiver phase interface alignment—critical for reproducible flux calculations (J = dQ/dt × 1/A, where J is steady-state flux, Q is cumulative amount permeated, t is time, and A is effective diffusion area). The system supports regulatory-compliant method development for topical, transdermal, and semi-solid dosage forms under GLP- and GMP-aligned laboratory environments.
Key Features
- Integrated bubble evacuation mechanism: Automated vacuum-assisted priming cycle removes entrapped air from membrane–donor interface prior to experiment initiation, eliminating measurement artifacts caused by interfacial voids.
- Double-jacketed water bath heating: Circulating thermostatic control maintains receiver compartment temperature within ±0.2 °C across all six cells, ensuring thermal equilibrium essential for Arrhenius-based permeability modeling.
- Light-shielded, insulated lid assembly: Reduces photodegradation risk for light-sensitive actives (e.g., retinoids, avobenzone) and minimizes evaporative loss during extended assays (up to 72 h).
- Modular silicone gasket set: Interchangeable gaskets (1.0 cm², 1.77 cm², and 3.14 cm² active diffusion areas) allow dose-normalized comparisons across formulations without altering experimental geometry.
- Dual-zone independent temperature control: Two thermally isolated zones (Zone A: Cells 1–3; Zone B: Cells 4–6) enable parallel testing of distinct thermal protocols—e.g., simulating skin surface (32 °C) vs. subcutaneous tissue (37 °C)—within a single run.
Sample Compatibility & Compliance
The FDC-6TA accommodates a broad range of semi-solid and liquid topical formulations including ointments, gels, creams, emulsions, hydroalcoholic solutions, patches, masks, sunscreens, and cleansing lotions. It accepts standard vertical diffusion cells with 10–15 mL receiver volumes and supports both natural (excised porcine/human epidermis) and synthetic membranes (Strat-M®, Epiderm™, Cellucoat®). All wetted components comply with USP Class VI plastics requirements. System validation documentation includes IQ/OQ protocols aligned with ASTM E2500-13 and supports FDA 21 CFR Part 11–compliant electronic record integrity when integrated with LOGAN’s WinControl software.
Software & Data Management
WinControl v5.2 software provides automated sampling scheduling, real-time flux monitoring, and kinetic model fitting (zero-order, first-order, Higuchi, Korsmeyer–Peppas). Data export is compliant with ASTM E1461-22 for thermal analysis metadata formatting and supports direct import into Phoenix WinNonlin® for PK/PD correlation. Audit trail functionality logs user actions, parameter changes, and calibration events with timestamped digital signatures—fully traceable for regulatory inspection. Raw data files are stored in vendor-neutral .csv and .xlsx formats, enabling third-party statistical analysis using JMP, R, or Python-based SciPy workflows.
Applications
- Comparative bioequivalence assessment of generic transdermal patches per FDA Guidance for Industry (2021)
- Formulation screening of penetration enhancers (e.g., terpenes, fatty acids, surfactants) via apparent permeability coefficient (Papp) derivation
- Stability-indicating release profiling of UV-filter-containing sunscreens under accelerated aging conditions
- Regulatory submission support for CMC sections of ANDAs and NDAs requiring in vitro release testing (IVRT) data
- Quality-by-Design (QbD) studies linking excipient composition to membrane partitioning behavior
FAQ
What membrane types are validated for use with the FDC-6TA?
Standard synthetic membranes (Strat-M®, Epiderm™) and excised porcine/human skin are fully supported. Validation reports for each membrane type—including thickness verification, barrier integrity testing (TEER), and blank diffusion rates—are available upon request.
Does the system meet USP mechanical requirements for flow rate and sampling precision?
Yes. The FDC-6TA’s peristaltic sampling module delivers ±1% volumetric accuracy at 0.5–2.0 mL intervals and maintains continuous flow rates between 0.1–5.0 mL/min, satisfying USP Section 4.2 specifications.
Can the dual-zone temperature control be programmed independently for each cell?
No. Zone-level control applies uniformly to Cells 1–3 (Zone A) and Cells 4–6 (Zone B). Individual cell temperature adjustment is not supported; however, zone-specific ramp/soak profiles may be defined.
Is WinControl software 21 CFR Part 11 compliant out-of-the-box?
Yes, when deployed on a validated Windows Server environment with domain-level authentication and encrypted database storage. Full Part 11 compliance requires site-specific SOP implementation and administrator role assignment.
